Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $16.00 | $3.20/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| GH202 | Apr 2026 | 98.0% | Vanguard Laboratory | Endotoxin, Sterility, Heavy metals | Unverified | View |
| hg2001 | Nov 2025 | 99.3% | Janoshik Analytical | — |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHRP-2 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Moglabs sell GHRP-2?
Yes — Moglabs currently lists GHRP-2 in 1 variant starting at $16.00 ($3.20/mg).
Is Moglabs's GHRP-2 third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Moglabs's GHRP-2, with the most recent showing 98.0% purity. Moglabs holds an overall trust grade of C (75/100) across all 38 COAs on file.
What is Moglabs's trust grade for GHRP-2?
Moglabs has an overall Disclosed Labs trust grade of C (75/100), computed from 38 COAs across all peptides. The most recent GHRP-2 COA was issued by Vanguard Laboratory.
Where is the cheapest GHRP-2?
As of the latest data, Verified Peptides offers GHRP-2 at $1.62/mg — compare with Moglabs's listing at $3.20/mg. See the full GHRP-2 price comparison.
Is GHRP-2 legal to buy?
GHRP-2 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| Unverified |
| View |
Disclosed Labs